Stoneridge Investment Partners LLC Takes $77,000 Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the fourth quarter, Holdings Channel.com reports. The fund purchased 10,893 shares of the company’s stock, valued at approximately $77,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Health Catalyst in the third quarter worth about $34,000. nVerses Capital LLC acquired a new position in Health Catalyst in the 3rd quarter worth about $59,000. Quadrature Capital Ltd purchased a new position in Health Catalyst during the third quarter worth approximately $84,000. Harbor Capital Advisors Inc. grew its holdings in Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Health Catalyst in the third quarter valued at approximately $145,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HCAT shares. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th. Canaccord Genuity Group decreased their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Piper Sandler reissued an “overweight” rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Stephens raised their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Finally, Royal Bank of Canada cut their price objective on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average price target of $10.60.

Insider Buying and Selling at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the transaction, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Benjamin Landry sold 19,268 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $160,309.76. Following the sale, the general counsel now owns 72,250 shares of the company’s stock, valued at approximately $601,120. The trade was a 21.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,169 shares of company stock worth $629,068 in the last three months. 2.50% of the stock is owned by corporate insiders.

Health Catalyst Trading Up 3.8 %

HCAT stock opened at $5.70 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average of $6.80 and a two-hundred day moving average of $7.42. Health Catalyst, Inc. has a 12 month low of $5.32 and a 12 month high of $10.31.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS. As a group, equities research analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.